A Feasibility Study to Collect Data in Patients With Haemophilia
Completed
- Conditions
- Hemophilia
- Interventions
- Other: Laboratory variables
- Registration Number
- NCT00798499
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this study is to collect reference data in patients with haemophilia. The study will also collect and store blood samples for potential future exploratory research in the disease area.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 50
Inclusion Criteria
- Provision of written informed consent
- Patients with haemophilia, all severities
- At least 18 years old.
Exclusion Criteria
- No exclusion criteria
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description 1 Laboratory variables Laboratory variables
- Primary Outcome Measures
Name Time Method Laboratory variables related to coagulation, SAEs in connection to blood sampling procedures will be collected, non-serious AEs will not be recorded The variables will be measured at first visit.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular biomarkers were identified in NCT00798499 hemophilia patient blood samples for future research?
How does NCT00798499 observational data compare to standard-of-care outcomes in hemophilia A/B populations?
Which FVIII/FIX activity levels correlate with inhibitor development in NCT00798499 hemophilia cohort?
What adverse event profiles were documented in AstraZeneca's hemophilia feasibility study NCT00798499?
How does NCT00798499 baseline data inform gene therapy or RNA-based approaches for hemophilia treatment?
Trial Locations
- Locations (1)
Research Site
🇸🇪Stockholm, Sweden